August 2, 2024 07:00 AM EDT
People
Peer Review

For­mer Rayze­Bio CEO quick­ly re­turns with new biotech; Am­gen’s glob­al re­search leader steps down

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Kyle LaHucik

Senior Reporter

Ken Song is back in busi­ness.

He left Rayze­Bio in Feb­ru­ary af­ter lead­ing the ra­dio­phar­ma­ceu­ti­cals start­up from Se­ries A to IPO in three years, and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times